Research in practice: Treatment of autoimmune bullous disorders
作者： Michael Hertl
DOI: 10.1111/J.1610-0387.2009.07023.X
关键词:
摘要: Autoimmune bullous disorders pose a clinical challenge based on their potentially lethal course and limited therapeutic options. The currently employed immunosuppressive treatments are accompanied by plethora of side effects. Therefore, our group has sought for many years to dissect the molecular mechanisms immune pathogenesis pemphigus pemphigoids allowing more specific treatment these disorders. We have extensively characterized role autoaggressive T cells potential regulatory networks in both contributed several tools refined serological cell-based disease parameters. ultimate goal is anergy induction which inititate perpetuate B cell-driven pemphigoids.
sci-hub.se 参考文章(24)
Alexander Enk, Michael Hertl, Gerald Messer, Michael Meurer, Ellen Rentz, Detlef Zillikens, Einsatz hochdosierter intravenöser Immunglobuline in der Dermatologie Journal Der Deutschen Dermatologischen Gesellschaft. ,vol. 1, pp. 183- 190 ,(2003) , 10.1046/J.1610-0387.2003.02028.X
Christian M. Veldman, Kerstin L. Gebhard, Wolfgang Uter, Ralf Wassmuth, Joachim Grötzinger, Erwin Schultz, Michael Hertl, T Cell Recognition of Desmoglein 3 Peptides in Patients with Pemphigus Vulgaris and Healthy Individuals Journal of Immunology. ,vol. 172, pp. 3883- 3892 ,(2004) , 10.4049/JIMMUNOL.172.6.3883
Christian Veldman, Andreas Pahl, Stefan Beissert, Wiebke Hansen, Jan Buer, Detlef Dieckmann, Gerold Schuler, Michael Hertl, Inhibition of the Transcription Factor Foxp3 Converts Desmoglein 3-Specific Type 1 Regulatory T Cells into Th2-Like Cells Journal of Immunology. ,vol. 176, pp. 3215- 3222 ,(2006) , 10.4049/JIMMUNOL.176.5.3215
Franziska Mayrshofer, Michael Hertl, Ronald Sinkgraven, Michael Sticherling, Christiane Pfeiffer, Detlef Zillikens, Gerald Messer, Berthold Rzany fur die deutscheBSD-Studiengr, Deutliche Einschränkung der Lebensqualität bei Patienten mit Pemphigus vulgaris: Ergebnisse der deutschen Bullous Skin Disease (BSD)‐Studiengruppe Journal Der Deutschen Dermatologischen Gesellschaft. ,vol. 3, pp. 431- 435 ,(2005) , 10.1111/J.1610-0387.2005.05722.X
Rüdiger Eming, Martin Pfütze, Michael Hertl, Andrea Niedermeier, Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus European Journal of Dermatology. ,vol. 17, pp. 4- 11 ,(2007) , 10.1684/EJD.2007.0090
Christian Veldman, Annette Höhne, Detlef Dieckmann, Gerold Schuler, Michael Hertl, Type I Regulatory T Cells Specific for Desmoglein 3 Are More Frequently Detected in Healthy Individuals than in Patients with Pemphigus Vulgaris The Journal of Immunology. ,vol. 172, pp. 6468- 6475 ,(2004) , 10.4049/JIMMUNOL.172.10.6468
Sybille Thoma-Uszynski, Wolfgang Uter, Susanne Schwietzke, Gerold Schuler, Luca Borradori, Michael Hertl, Autoreactive T and B Cells from Bullous Pemphigoid (BP) Patients Recognize Epitopes Clustered in Distinct Regions of BP180 and BP230 The Journal of Immunology. ,vol. 176, pp. 2015- 2023 ,(2006) , 10.4049/JIMMUNOL.176.3.2015
Christian Veldman, Angelika Stauber, Ralf Wassmuth, Wolfgang Uter, Gerold Schuler, Michael Hertl, Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. Journal of Immunology. ,vol. 170, pp. 635- 642 ,(2003) , 10.4049/JIMMUNOL.170.1.635
Ralf Muller, Vera Svoboda, Elke Wenzel, Susanne Gebert, Nicolas Hunzelmann, Hans-Helge Muller, Michael Hertl, IgG reactivity against non‐conformational NH2‐terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris Experimental Dermatology. ,vol. 15, pp. 606- 614 ,(2006) , 10.1111/J.1600-0625.2006.00451.X
M. Hertl, T cell control in autoimmune bullous skin disorders Journal of Clinical Investigation. ,vol. 116, pp. 1159- 1166 ,(2006) , 10.1172/JCI28547